Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Chubb
Mallinckrodt
Cerilliant
Boehringer Ingelheim
US Army
McKesson
Covington
Chinese Patent Office

Generated: April 23, 2018

DrugPatentWatch Database Preview

CYCLOSET Drug Profile

« Back to Dashboard

Which patents cover Cycloset, and when can generic versions of Cycloset launch?

Cycloset is a drug marketed by Veroscience and is included in one NDA. There are eleven patents protecting this drug.

This drug has twenty-two patent family members in twelve countries.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Summary for CYCLOSET
Drug patent expirations by year for CYCLOSET
Pharmacology for CYCLOSET
Ingredient-typeErgolines
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for CYCLOSET
Synonyms for CYCLOSET
.alpha.-Ergocryptine, methanesulfonate
(+)-Bromocriptine methanesulfonate
(4R,7R)-10-BROMO-N-[(1S,2S,4R,7S)-2-HYDROXY-7-(2-METHYLPROPYL)-5,8-DIOXO-4-(PROPAN-2-YL)-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),2,9,12,14-PENT
(5 inverted exclamation mark |A)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Methanesulfonate
(5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mesylate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman methanesulfonate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (salt)
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate
(5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt)
(5xi,5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (salt)
(6AR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
(6aR,9R)-5-Bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quin
2-Bromine-alpha-ergocryptine methanesulfonate
2-Bromo |A-Ergocryptine Mesylate
2-Bromo alpha-Ergocryptine Mesylate
2-Bromo-.alpha.-ergocryptine monomethanesulfonate
2-Bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate
2-Bromo-a-ergocryptine methanesulfonate salt
2-Bromo-alpha-ergocryptine mesylate
2-Bromo-alpha-ergocryptine methanesulfonate
2-Bromo-alpha-ergokryptine-mesilate
2-Bromo-alpha-ergokryptine-mesilate [German]
2-Bromoergocryptine
2-Bromoergocryptine monomethanesulfonate (salt)
22260-51-1
25614-03-3 (Parent)
93201-EP2272825A2
93201-EP2305633A1
AC1L1KXP
AK397268
AKOS015896276
alpha-Ergocryptine, 2-bromo-, methanesulfonate
AN-17214
B 2134
B6298
Bagren
Bromergon
Bromocriptine (mesylate)
Bromocriptine mesilate
Bromocriptine mesilate (JP17)
BROMOCRIPTINE MESYLATE
Bromocriptine mesylate (USP)
Bromocriptine mesylate [USAN:USP]
Bromocriptine mesylate [USAN]
Bromocriptine methanesulfonate
Bromocryptine mesylate
Bromocryptine methanesulfonate
C32H40BrN5O5.CH4O3S
CAS-22260-51-1
CB 154
CB 154 methanesulfonate (salt)
CB-154
CB-154 mesylate
CCG-220121
CCG-221475
CHEBI:3182
CHEMBL1200503
CS-6048
D00780
DSSTox_CID_197
DSSTox_GSID_20197
DSSTox_RID_75426
DTXSID6020197
EINECS 244-881-1
Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-
EU-0100171
FFP983J3OD
HMS1568I04
HMS3260D03
HY-12705A
I06-2158
LP00171
LS-7234
MolPort-006-123-738
NCGC00257268-01
NCGC00260856-01
NOJMTMIRQRDZMT-GSPXQYRGSA-N
NSC-169774
NSC169774
oline-9-carboxamide methanesulfonate
Parlodel (TN)
PL011661
Pravidel
Prestwick_771
SCHEMBL40559
SR-01000075356
SR-01000075356-1
Tox21_303597
Tox21_500171
UNII-FFP983J3OD

US Patents and Regulatory Information for CYCLOSET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CYCLOSET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for CYCLOSET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,895,422 Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Argus Health
Daiichi Sankyo
US Army
AstraZeneca
Teva
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.